Signal, buried.
Thousands of trials, abstracts and filings land every month. The one move that changes your strategy is in there. You just can't surface it in time.
COMPETITIVE INTELLIGENCE · ONCOLOGY-ONLY
Oncology competitive intelligence, before the landscape moves.
Prognyx turns trials, readouts, deals and regulatory moves into one sourced answer for your asset and your next decision, delivered as a five-business-day pilot. Each claim links to a primary source; automated checks remove what its source does not carry.
Registry, FDA, EMA, SEC, company releases
5 days scope-to-brief
1 focus, oncology
[ 01 ] THE PROBLEM
The field moves faster than any team can track.
Tools, not answers.
A six-figure database hands you data to mine. A consulting project hands you a deck, once. Neither watches your back on a Tuesday afternoon.
Priced for giants.
Enterprise intelligence is built for big-pharma budgets. The biotech with the most riding on a single asset is the one left flying blind.
Registry, FDA, EMA, SEC
and company releases: the primary records a briefing links to, wherever one exists
5 days
business days from agreed scope to delivered brief
1
therapeutic focus, oncology, and nothing else
[ 02 ] WHAT PROGNYX DOES
Oncology competitive intelligence, focused on one decision.
Not a portal to mine or a six-week consulting project. One asset, one indication and one decision question, researched, sourced and delivered as a concise brief.
- Bounded. The question, evidence set and deadline are agreed before work starts.
- Sourced. Every claim traces back to the primary record, NCT, label, abstract, filing.
- Decision-ready. The so-what and the now-what, not a data dump.
- Tailored. Scoped to your assets, mechanisms and indications.
COMPETITIVE BRIEF
LIVE WATCH
KRAS G12C, second-line NSCLC
Competitor readoutESMO 2026
Threat levelElevated
Window to act~6 weeks
78
A rival's confirmatory data lands before your filing. Here's the angle, the risk to your positioning, and the three moves on the table.
SOURCED · ClinicalTrials.gov · ESMO abstract · FDA label
[ 03 ] HOW IT WORKS
From noise
to a decision,
in four moves.
Define
We map your competitive set, targets, mechanisms, indications and the assets that can move your value.
SCOPEWatch
We track trials, congress readouts, regulatory actions, deals and publications, straight to the primary source.
MONITORSynthesize
We turn it into what it means for you and what to do next, sharp, sourced, no filler.
ANALYZEDecide
You get briefs your team actually reads and forwards, plus answers on demand when the field shifts.
ACTThe next move,
first.
Scope the pilot→
[ 04 ] WHY PROGNYX
Not a database. Not a $150k deck. Your analyst.
Prognyx
Data platforms
Consulting
One defined decision scope
Tailored to your pipeline
Decision-ready (the so-what)
Oncology-deep
Days, not weeks
Accessible to a single-asset biotech
We don't out-database the giants. We out-matter them on the one question they can't answer for you: what do I do about this, on my molecule, this week?
[ 05 ] FROM THE WATCHTOWER
Oncology intelligence, in the open.
FDA approves atezolizumab plus chemo for adjuvant Stage III dMMR colon cancer
Genentech's atezolizumab moves from unresectable, metastatic dMMR tumors into curative-intent adjuvant therapy for resected Stage III colon cancer, cleared on the ATOMIC…
Read briefing →
FDA approves Pfizer's tucatinib triplet for HER2-positive breast cancer maintenance
The 7 October approval adds oral tucatinib to a trastuzumab and pertuzumab maintenance backbone after induction, on the strength of the 654-patient HER2CLIMB-05 trial…
Read briefing →
AbbVie's c-Met ADC wins dual FDA Breakthrough Therapy tags in CRC and lung cancer
The c-Met antibody-drug conjugate ABBV-400, carrying a topoisomerase 1 inhibitor payload, gains US Breakthrough Therapy Designation in colorectal and non-small cell lung…
Read briefing →
Epcoritamab plus R-CHOP cuts first-line DLBCL progression risk 51% in Phase 3
Genmab and AbbVie's CD3xCD20 bispecific added to R-CHOP met the Phase 3 trial's primary endpoint in newly diagnosed DLBCL; in all enrolled patients (IPI 2-5, a key…
Read briefing →
Revolution Medicines begins dosing its RAS(ON) doublet in G12D pancreatic cancer
Revolution Medicines has begun treating patients in RASolute 309 (NCT07805954), a global Phase 3 study pitting its RAS(ON) doublet against gemcitabine and nab-paclitaxel…
Read briefing →
FDA clears Lilly's pirtobrutinib for untreated CLL without 17p deletion
The 2 October approval, based on BRUIN CLL-313 versus bendamustine plus rituximab, moves Lilly's reversible BTK inhibitor from relapsed mantle cell lymphoma into…
Read briefing →[ 06 ] THE OFFER
See the next move first.
Tell us the asset, indication and decision you need to clarify. We will confirm the scope and fee of a one-off pilot in writing, delivered in five business days.
How Prognyx knows this
Every claim is built from primary sources only, and traces back to a document you can open. No opinion you can't check.
Who's behind it
Rali Filali, founder of Prognyx · M.D. candidate. Independent, no platform or bank behind the read. Every brief is audited against the primary record before it reaches you. Competitive analysis of public information, not medical or investment advice.
One-off pilot, one asset, one indication and one defined decision question, delivered in five business days with one written revision, at a fixed fee confirmed in writing. See the exact scope
Need it every month? Join the waitlist for a monthly source-linked feed on one target (page, CSV and alerts). See the KRAS G12C example
ONCOLOGY COMPETITIVE INTELLIGENCE · PROGNYX